Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.62 (
caspase-9
)
7,507
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cardiac remodeling and dysfunction are responsible for the high mortality after myocardial infarction (MI). We assessed the potential for
Shank3
to alleviate the post-infarction cardiac dysfunction. The experimental MI mice model was constructed by left anterior descending coronary artery ligation.
Shank3
knockout aggravated cardiac dysfunction after MI, while
Shank3
overexpression alleviated it. The histological examination showed that the infarct size was significantly increased in the acute phase of MI in the
Shank3
knockout group, and the cardiac dysfunction of the
Shank3
knockout group was even more severe than the
Shank3
overexpression group, revealed by echocardiography analyses.
In vitro
, cultured neonatal cardiomyocytes were subjected to simulated MI.
Shank3
downregulation curbed LC3 expression and autophagosome-lysosome fusion. Furthermore,
Shank3
downregulation increased cardiomyocyte apoptosis. In contrast,
Shank3
upregulation induced autophagy, and inhibited apoptosis under hypoxia.
In vivo
, western blot analysis showed decreased levels of Atg7, Beclin1, LC3-II, and Bcl-2 as well as increased expression of p62, cleaved caspase-3, and cleaved
caspase-9
in the
Shank3
knockout group which suffered from MI. On the other hand, it also revealed that
Shank3
overexpression induced autophagy and inhibited apoptosis after MI.
Shank3
may serve as a new target for improving cardiac function after MI by inducing autophagy while inhibiting apoptosis.
...
PMID:SHANK3 Co-ordinately Regulates Autophagy and Apoptosis in Myocardial Infarction. 3298 97